Nordea Investment Management AB Raises Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

Nordea Investment Management AB lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 74.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 372,282 shares of the biotechnology company’s stock after buying an additional 158,937 shares during the period. Nordea Investment Management AB’s holdings in Arrowhead Pharmaceuticals were worth $12,661,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Royal Bank of Canada boosted its holdings in shares of Arrowhead Pharmaceuticals by 30.2% during the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 10,496 shares during the last quarter. AQR Capital Management LLC purchased a new position in Arrowhead Pharmaceuticals during the first quarter worth about $514,000. Goldman Sachs Group Inc. lifted its position in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares during the period. Empowered Funds LLC boosted its stake in Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after buying an additional 979 shares during the last quarter. Finally, Focus Partners Wealth grew its holdings in Arrowhead Pharmaceuticals by 1,339.5% in the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 15,123 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ARWR. Chardan Capital increased their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Royal Bank Of Canada increased their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Bank of America lifted their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. HC Wainwright upped their price objective on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $73.00.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $66.25 on Friday. The company’s fifty day simple moving average is $59.36 and its 200-day simple moving average is $37.88. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $76.76. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The company has a market cap of $9.00 billion, a PE ratio of -828.02 and a beta of 1.21.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 40,164 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the transaction, the insider owned 171,958 shares in the company, valued at $10,852,269.38. The trade was a 18.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Patrick O’brien sold 49,493 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the sale, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at $29,971,443.88. The trade was a 9.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 510,836 shares of company stock valued at $33,603,060. 4.30% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.